Bulk Manufacturer of Controlled Substances Application: Chattem Chemicals, 11557-11558 [2021-03836]

Download as PDF Federal Register / Vol. 86, No. 36 / Thursday, February 25, 2021 / Notices investigation. The Commission is soliciting submissions on public interest issues raised by the recommended relief should the Commission find a violation. This notice is soliciting comments from the public only. FOR FURTHER INFORMATION CONTACT: Benjamin S. Richards, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 708–5453. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission’s electronic docket (EDIS) at https://edis.usitc.gov. For help accessing EDIS, please email EDIS3Help@usitc.gov. General information concerning the Commission may also be obtained by accessing its internet server at https://www.usitc.gov. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205–1810. SUPPLEMENTARY INFORMATION: Parties are to file public interest submissions pursuant to 19 CFR 210.50(a)(4). Section 337 of the Tariff Act of 1930 provides that, if the Commission finds a violation, it shall exclude the articles concerned from the United States: unless, after considering the effect of such exclusion upon the public health and welfare, competitive conditions in the United States economy, the production of like or directly competitive articles in the United States, and United States consumers, it finds that such articles should not be excluded from entry. 19 U.S.C. 1337(d)(1). A similar provision applies to cease and desist orders. 19 U.S.C. 1337(f)(1). The Commission is soliciting submissions on public interest issues raised by the recommended relief should the Commission find a violation, specifically: A limited exclusion order directed to certain collapsible and portable furniture imported, sold for importation, and/or sold after importation by respondents Denovo Brands, LLC; Zhenli (Zhangzhou) Industrial Co., Ltd. (‘‘Denovo’’); Meike (Qingdao) Leisure Products Co., Ltd.; Westfield Outdoor, Inc. d/b/a Westfield Outdoors (‘‘Westfield’’); and MacSports Inc. (‘‘MacSports’’); and cease and desist orders directed to Denovo, Westfield, and MacSports. The Commission is interested in further development of the record on the public interest in this investigation. Accordingly, members of the public are invited to file submissions of no more than five (5) pages, inclusive of attachments, concerning the public VerDate Sep<11>2014 17:04 Feb 24, 2021 Jkt 253001 interest in light of the ALJ’s Recommended Determination on Remedy and Bonding issued in this investigation on February 18, 2021. Comments should address whether issuance of the recommended remedial orders in this investigation, should the Commission find a violation, would affect the public health and welfare in the United States, competitive conditions in the United States economy, the production of like or directly competitive articles in the United States, or United States consumers. In particular, the Commission is interested in comments that: (i) explain how the articles potentially subject to the recommended remedial orders are used in the United States; (ii) identify any public health, safety, or welfare concerns in the United States relating to the recommended orders; (iii) identify like or directly competitive articles that complainant, its licensees, or third parties make in the United States which could replace the subject articles if they were to be excluded; (iv) indicate whether complainant, complainant’s licensees, and/or thirdparty suppliers have the capacity to replace the volume of articles potentially subject to the recommended orders within a commercially reasonable time; and (v) explain how the recommended orders would impact consumers in the United States. Written submissions must be filed no later than by close of business on March 22, 2021. Persons filing written submissions must file the original document electronically on or before the deadlines stated above. The Commission’s paper filing requirements in 19 CFR 210.4(f) are currently waived. 85 FR 15798 (March 19, 2020). Submissions should refer to the investigation number (‘‘Inv. No. 337–TA–1178’’) in a prominent place on the cover page and/or the first page. (See Handbook for Electronic Filing Procedures, https:// www.usitc.gov/documents/handbook_ on_filing_procedures.pdf.) Persons with questions regarding filing should contact the Secretary (202–205–2000). Any person desiring to submit a document to the Commission in confidence must request confidential treatment. All such requests should be directed to the Secretary to the Commission and must include a full statement of the reasons why the Commission should grant such treatment. See 19 CFR 201.6. Documents for which confidential treatment by the Commission is properly sought will be PO 00000 Frm 00063 Fmt 4703 Sfmt 4703 11557 treated accordingly. All information, including confidential business information and documents for which confidential treatment is properly sought, submitted to the Commission for purposes of this Investigation may be disclosed to and used: (i) By the Commission, its employees and Offices, and contract personnel (a) for developing or maintaining the records of this or a related proceeding, or (b) in internal investigations, audits, reviews, and evaluations relating to the programs, personnel, and operations of the Commission including under 5 U.S.C. Appendix 3; or (ii) by U.S. government employees and contract personnel, solely for cybersecurity purposes. All contract personnel will sign appropriate nondisclosure agreements. All nonconfidential written submissions will be available for public inspection on EDIS. This action is taken under the authority of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210). By order of the Commission. Issued: February 19, 2021. Lisa Barton, Secretary to the Commission. [FR Doc. 2021–03855 Filed 2–24–21; 8:45 am] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–789] Bulk Manufacturer of Controlled Substances Application: Chattem Chemicals Drug Enforcement Administration, Justice. ACTION: Notice of application. AGENCY: Chattem Chemicals has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before April 26, 2021. Such persons may also file a written request for a hearing on the application on or before April 26, 2021. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal SUMMARY: E:\FR\FM\25FEN1.SGM 25FEN1 11558 Federal Register / Vol. 86, No. 36 / Thursday, February 25, 2021 / Notices Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. In accordance with 21 CFR 1301.33(a), this is notice that on July 20, 2020, Chattem Chemicals 3801 Saint Elmo Avenue, Chattanooga, Tennessee 37409, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s): SUPPLEMENTARY INFORMATION: Controlled substance Drug code Gamma Hydroxybutyric Acid .... Marihuana ................................. Tetrahydrocannabinols ............. 4-Methoxyamphetamine ........... Dihydromorphine ....................... Norlevorphanol .......................... Amphetamine ............................ Methamphetamine .................... Lisdexamfetamine ..................... Methylphenidate ........................ ANPP (4-Anilino-N-phenethyl-4piperidine). Phenylacetone .......................... Cocaine ..................................... Codeine ..................................... Dihydrocodeine ......................... Oxycodone ................................ Hydromorphone ........................ Hydrocodone ............................. Levorphanol .............................. Meperidine ................................ Meperidine intermediate–A ....... Meperidine intermediate–B ....... Meperidine intermediate–C ....... Methadone ................................ Methadone intermediate ........... Morphine ................................... Oripavine ................................... Thebaine ................................... Opium, powdered ..................... Opium, granulated .................... Oxymorphone ........................... Noroxymorphone ...................... Racemethorphan ...................... Alfentanil ................................... Remifentanil .............................. Sufentanil .................................. Tapentadol ................................ Fentanyl .................................... Schedule 2010 7360 7370 7411 9145 9634 1100 1105 1205 1724 8333 I I I I I I II II II II II 8501 9041 9050 9120 9143 9150 9193 9220 9230 9232 9233 9234 9250 9254 9300 9330 9333 9639 9640 9652 9668 9732 9737 9739 9740 9780 9801 II II II II II II II II II II II II II II II II II II II II II II II II II II II [FR Doc. 2021–03836 Filed 2–24–21; 8:45 am] BILLING CODE 4410–09–P VerDate Sep<11>2014 17:04 Feb 24, 2021 Jkt 253001 Drug Enforcement Administration [Docket No. DEA–791] Bulk Manufacturer of Controlled Substances Application: S&B Pharma, Inc. Drug Enforcement Administration, Justice. AGENCY: ACTION: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before April 26, 2021. Such persons may also file a written request for a hearing on the application on or before April 26, 2021. DATES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. ADDRESSES: In accordance with 21 CFR 1301.33(a), this is notice that on November 11, 2020, S&B Pharma, Inc., 405 South Motor Avenue, Azusa, California 91702–3232, applied to be registered as an bulk manufacturer of the following basic class(es) of controlled substance(s): SUPPLEMENTARY INFORMATION: Gamma Hydroxybutyric Acid .... Tetrahydrocannabinols ............. Amphetamine ............................ Methamphetamine .................... Lisdexamfetamine ..................... Methylphenidate ........................ Pentobarbital ............................. 4-Anilino-N-phenethyl-4-piperidine (ANPP). Tapentadol ................................ Fentanyl .................................... Drug code Schedule 7360 7370 1100 1105 1205 1724 2270 8333 I I II II II II II II 9780 9801 II II The company plans to manufacture the listed controlled substances in bulk for use in product development and for commercial sales to its customers. In reference to drug code 7360 (Marihuana) and 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture both as synthetic substances. No other Frm 00064 Fmt 4703 DEPARTMENT OF JUSTICE [Docket No. DEA798] Notice of application. Controlled substance BILLING CODE 4410–09–P Drug Enforcement Administration S&B Pharma, Inc., has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information. PO 00000 William T. McDermott, Assistant Administrator. [FR Doc. 2021–03837 Filed 2–24–21; 8:45 am] SUMMARY: The company plans to manufacturer the listed controlled substances in bulk for distribution and sale to its customers. In reference to drug code 7360 (Marihuana) and 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture these drugs as a synthetic. No other activities for this drug code are authorized for this registration. William T. McDermott, Assistant Administrator. activity for these drug codes is authorized for this registration. DEPARTMENT OF JUSTICE Sfmt 4703 Importer of Controlled Substances Application: Myonex Inc Drug Enforcement Administration, Justice. ACTION: Notice of application. AGENCY: Myonex Inc has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information. SUMMARY: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before March 29, 2021. Such persons may also file a written request for a hearing on the application on or before March 29, 2021. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All request for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on January 6, 2021, Myonex Inc, 48 East Main Street, Norristown, Pennsylvania 19401–4915, applied to be registered as an importer of the following basic class(es) of controlled substance(s): DATES: Controlled substance Amphetamine ................. Lisdexamfetamine .......... Methylphenidate ............. E:\FR\FM\25FEN1.SGM 25FEN1 Drug code Schedule 1100 1205 1724 II II II

Agencies

[Federal Register Volume 86, Number 36 (Thursday, February 25, 2021)]
[Notices]
[Pages 11557-11558]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-03836]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-789]


Bulk Manufacturer of Controlled Substances Application: Chattem 
Chemicals

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Chattem Chemicals has applied to be registered as a bulk 
manufacturer of basic class(es) of controlled substance(s). Refer to 
Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may file written comments on or objections to 
the issuance of the proposed registration on or before April 26, 2021. 
Such persons may also file a written request for a hearing on the 
application on or before April 26, 2021.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal

[[Page 11558]]

Register Representative/DPW, 8701 Morrissette Drive, Springfield, 
Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this 
is notice that on July 20, 2020, Chattem Chemicals 3801 Saint Elmo 
Avenue, Chattanooga, Tennessee 37409, applied to be registered as a 
bulk manufacturer of the following basic class(es) of controlled 
substance(s):

------------------------------------------------------------------------
                                           Drug
          Controlled substance             code          Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid...............    2010  I
Marihuana...............................    7360  I
Tetrahydrocannabinols...................    7370  I
4-Methoxyamphetamine....................    7411  I
Dihydromorphine.........................    9145  I
Norlevorphanol..........................    9634  I
Amphetamine.............................    1100  II
Methamphetamine.........................    1105  II
Lisdexamfetamine........................    1205  II
Methylphenidate.........................    1724  II
ANPP (4-Anilino-N-phenethyl-4-              8333  II
 piperidine).
Phenylacetone...........................    8501  II
Cocaine.................................    9041  II
Codeine.................................    9050  II
Dihydrocodeine..........................    9120  II
Oxycodone...............................    9143  II
Hydromorphone...........................    9150  II
Hydrocodone.............................    9193  II
Levorphanol.............................    9220  II
Meperidine..............................    9230  II
Meperidine intermediate-A...............    9232  II
Meperidine intermediate-B...............    9233  II
Meperidine intermediate-C...............    9234  II
Methadone...............................    9250  II
Methadone intermediate..................    9254  II
Morphine................................    9300  II
Oripavine...............................    9330  II
Thebaine................................    9333  II
Opium, powdered.........................    9639  II
Opium, granulated.......................    9640  II
Oxymorphone.............................    9652  II
Noroxymorphone..........................    9668  II
Racemethorphan..........................    9732  II
Alfentanil..............................    9737  II
Remifentanil............................    9739  II
Sufentanil..............................    9740  II
Tapentadol..............................    9780  II
Fentanyl................................    9801  II
------------------------------------------------------------------------

    The company plans to manufacturer the listed controlled substances 
in bulk for distribution and sale to its customers.
    In reference to drug code 7360 (Marihuana) and 7370 
(Tetrahydrocannabinols), the company plans to bulk manufacture these 
drugs as a synthetic. No other activities for this drug code are 
authorized for this registration.

William T. McDermott,
Assistant Administrator.
[FR Doc. 2021-03836 Filed 2-24-21; 8:45 am]
BILLING CODE 4410-09-P